| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-55744 | |||
| BSA Free | NB100-56618SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB120-13550-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56518SS | |||
| Azide and BSA Free | NBP2-80989 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-97453-0.2mg | |||
| BSA Free | NBP1-97453-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-74578 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-71043 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-89034-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-78785SS | |||
![Western Blot: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Total protein from HL-60, HepG2, HCT-116 and human placenta was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TRAIL R2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-Western-Blot-NB100-56618-img0005.jpg "Western Blot: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Total protein from HL-60, HepG2, HCT-116 and human placenta was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TRAIL R2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis of a formalin fixed paraffin-embedded (FFPE) human brain cerebellum using 1:200 conc. of TRAIL R2/TNFRSF10B antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 30 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 9.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 15 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Cytoplasmic staining was observed in the Purkinje cell layer.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-Immunohistochemistry-Paraffin-NB100-56618-img0007.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: TRAILR2/TNFRSF10B Antibody [NB100-56618] - Pharmacodynamic assays for ONC201. IHC analyses of CHOP, TRAILR2/TNFRSF10B, and double-stranded DNA breaks (TUNEL) in baseline and ONC201-treated biopsies for an endometrial cancer patient. The biopsy was done 9.8 months after starting ONC201 treatment (7 days after the most recent ONC201 dose). Image collected and cropped by CiteAb from the following publication (//jitc.biomedcentral.com/articles/10.1186/s40425-019-0599-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRAILR2-TNFRSF10B-Antibody-Immunohistochemistry-NB100-56618-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-TRAIL R2 (H76) at 5ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-Immunocytochemistry-Immunofluorescence-NB100-56618-img0004.jpg)
![Western Blot: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis using the Azide Free version of NB100-56618. Detection of 20 ug of whole cell lysates from HL60 cells with anti-TRAIL-R2 at 5 ug/ml.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-Western-Blot-NB100-56618-img0003.jpg)
![Western Blot: IRF5 Antibody [NB100-1092] - Western blot analysis of Human Spleen (A) and A549 cell lysate (B) + peptide (C), 35 ug protein in RIPA buffer. Antibody at 1 ug/mL. Detected by chemiluminescence](http://images.novusbio.com/fullsize/IRF5-Antibody-Western-Blot-NB100-1092-img0004.jpg "Western Blot: IRF5 Antibody [NB100-1092] - Western blot analysis of Human Spleen (A) and A549 cell lysate (B) + peptide (C), 35 ug protein in RIPA buffer. Antibody at 1 ug/mL. Detected by chemiluminescence")
![<b>Genetic Strategies Validation. </b>Western Blot: IRF5 Antibody [NB100-1092] - Endogenous IRF5 knockdown analysis. Ramos B cells were nucleofected with scrambled (Scr) or IRF5 (KD) siRNAs and lysates from same nucleofection run on multiple independent blots for comparative analysis of seven different commercially available alpha-IRF5 antibodies. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data are representative of three independent experiments. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep31002), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IRF5-Antibody-Western-Blot-NB100-1092-img0003.jpg)
![Western Blot: IRF5 Antibody [NB100-1092] - Comparative analysis of IRF5 protein expression between immortalized lymphoid cell lines by immunoblot. Endogenous IRF5 protein expression in lysates (T, THP-1; R, Ramos B cells; J, Jurkat T cells) was detecting by running multiple independent blots for the analysis of antibody specificity; seven different commercially available alpha-IRF5 antibodies were evaluated. IRF5 expression was detected with the previously validated Cell Signaling antibody #3257 that is no longer available. beta-actin levels and apparent molecular weight standards are shown as loading controls and for size comparison, respectively. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data are representative of three independent experiments. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep31002), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IRF5-Antibody-Western-Blot-NB100-1092-img0002.jpg)
![Western Blot: IRF5 Antibody [NB100-1092] - Overexpression of IRF5 in MCF-7 & MDA-MB-231 cells sensitizes them to DNA damage-induced growth inhibition. A. Endogenous IRF expression was analyzed by Western blot in transformed mammary epithelial cell lines. Levels of beta -actin are shown as loading controls. B. Western blot analysis of stable cell lines generated to overexpress retroviral pBIRF5. C. Cell survival was measured in MCF-7 & MDA-MB-231 pBabe cell lines by colony formation assay before & after treatment. Cells were treated with 0.1 or 1 μM Doxorubicin (Dox) or 2, 5 & 10 Gy gamma -IR. The number of colonies is plotted on the y-axis as percent of control; 100% represents the number of colonies in empty pBabe control lines. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in pBabe versus pBIRF5 cell lines after each treatment; * denotes P 70% reduction of endogenous IRF5 proteins after normalization to beta -actin levels. B. Cells were exposed to 5 Gy IR or the same dose plus IFN-gamma (IR/ gamma ) for 24 h. Percent of Annexin V-FITC stained positive cells is shown in the upper & lower right-hand quadrants. Representative histogram plots from three independent experiments performed in duplicate are shown. C. Same as in B, except cells were exposed to 1 μM Dox or Dox & IFN-gamma for five hours. Percent of Annexin V-FITC stained positive cells compared to control is plotted on y-axis. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between cells transfected with Lamin A/C siRNAs (12Asicon) & IRF5 siRNAs (12AsiIRF5) after each treatment; ** denotes P < 0.001. D. Cells were treated with the indicated doses of Dox or IR after siRNA transfection. Number of colonies is plotted on y-axis as percent of control. A total of 100% represents the number of colonies in control untreated 12Asicon cells. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in 12Asicon versus 12AsiIRF5 cells after each treatment; * denotes P < 0.05. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3053), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1092_goat-polyclonal-irf5-antibody-imgenex-img-3525-31020241612691.jpg)
![Western Blot: IRF5 Antibody [NB100-1092] - Comparative analysis of IRF5 protein expression between immortalized lymphoid cell lines by immunoblot.(A) qRT-PCR analysis of IRF5 transcript expression in immortalized lymphoid cell lines. Data is presented as relative expression after normalization to beta -actin using the ∆∆Ct method. (B) Immunoblot analysis of endogenous IRF5 protein expression in immortalized cell lines. IRF5 expression was detected with the previously validated Cell Signaling antibody #3257 that is no longer available. beta -actin levels & apparent molecular weight standards are shown as loading controls & for size comparison, respectively. (C) Experimental details for the comparative analysis of alpha -IRF5 antibody specificity by immunoblot analysis. (D) Same as in (B)except lysates (T, THP-1; R, Ramos B cells; J, Jurkat T cells) were run on multiple independent blots for the analysis of antibody specificity; seven different commercially available alpha -IRF5 antibodies were evaluated. (E) Same as in (D) except antibodies were evaluated by IRF5 knockdown analysis. Ramos B cells were nucleofected with scrambled (Scr) or IRF5 (KD) siRNAs & lysates from same nucleofection run on multiple independent blots for comparative analysis. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data (except in (C)) are representative of three independent experiments. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep31002), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1092_goat-polyclonal-irf5-antibody-imgenex-img-3525-310202415525278.jpg)
![Western Blot: IRF5 Antibody [NB100-1092] - Overexpression of IRF5 in MCF-7 & MDA-MB-231 cells sensitizes them to DNA damage-induced growth inhibition. A. Endogenous IRF expression was analyzed by Western blot in transformed mammary epithelial cell lines. Levels of beta -actin are shown as loading controls. B. Western blot analysis of stable cell lines generated to overexpress retroviral pBIRF5. C. Cell survival was measured in MCF-7 & MDA-MB-231 pBabe cell lines by colony formation assay before & after treatment. Cells were treated with 0.1 or 1 μM Doxorubicin (Dox) or 2, 5 & 10 Gy gamma -IR. The number of colonies is plotted on the y-axis as percent of control; 100% represents the number of colonies in empty pBabe control lines. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in pBabe versus pBIRF5 cell lines after each treatment; * denotes P < 0.05, ** P < 0.001. Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3053), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1092_goat-polyclonal-irf5-antibody-imgenex-img-3525-31020241553200.jpg)
![Western Blot: Fas Receptor/TNFRSF6/CD95 Antibody [NB120-13550] - Fas/TNFRSF6/CD95 Antibody [NB120-13550] - Lane 1: Rat Brain Tissue Extract. Lane 2: Mouse Brain Tissue Extract.](http://images.novusbio.com/fullsize/Fas-TNFRSF6-CD95-Antibody-Western-Blot-NB120-13550-img0007.jpg "Western Blot: Fas Receptor/TNFRSF6/CD95 Antibody [NB120-13550] - Fas/TNFRSF6/CD95 Antibody [NB120-13550] - Lane 1: Rat Brain Tissue Extract. Lane 2: Mouse Brain Tissue Extract.")
![Immunocytochemistry/Immunofluorescence: Fas Receptor/TNFRSF6/CD95 Antibody [NB120-13550] - Representative IF of cerebellar sections at P10 using an anti-CD95/Fas antibody (green), an anti-calbindin antibody (red) to highlight Purkinje cells. For IF, Hoechst dye (blue) was used to mark nuclei. Scale bar 50 um. Image collected and cropped by CiteAb from the following publication (jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-017-0838-1), licensed under a CC-BY license](http://images.novusbio.com/fullsize/Fas-Receptor-TNFRSF6-CD95-Antibody-Immunocytochemistry-Immunofluorescence-NB120-13550-img0008.jpg)
![Immunohistochemistry-Paraffin: Fas Receptor/TNFRSF6/CD95 Antibody [NB120-13550] - Analysis of human colon tumor tissue stained with Fas polyclonal antibody, at 10ug/ml.](http://images.novusbio.com/fullsize/Fas-Receptor-TNFRSF6-CD95-Antibody-Immunohistochemistry-Paraffin-NB120-13550-img0010.jpg)
![Immunohistochemistry-Paraffin: Fas Receptor/TNFRSF6/CD95 Antibody [NB120-13550] - Analysis of human spleen tissue stained with Fas polyclonal antibody, at 10ug/ml.](http://images.novusbio.com/fullsize/Fas-Receptor-TNFRSF6-CD95-Antibody-Immunohistochemistry-Paraffin-NB120-13550-img0009.jpg)
![Western Blot: TRAIL/TNFSF10 Antibody (55B709.3) [NB100-56518] - Analysis of TRAIL in Jurkat lysate](http://images.novusbio.com/fullsize/TRAIL-TNFSF10-Antibody-55B709-3-Western-Blot-NB100-56518-img0006.jpg "Western Blot: TRAIL/TNFSF10 Antibody (55B709.3) [NB100-56518] - Analysis of TRAIL in Jurkat lysate")
![Immunohistochemistry-Paraffin: TRAIL/TNFSF10 Antibody (55B709.3) [NB100-56518] - Analysis of TRAIL in human kidney using TRAIL antibody at 5 ug/ml.](http://images.novusbio.com/fullsize/TRAIL-TNFSF10-Antibody-55B709-3-Immunohistochemistry-Paraffin-NB100-56518-img0005.jpg)
![Western Blot: TNF RI/TNFRSF1A Antibody [NBP1-97453] - TNF-R1 Antibody [NBP1-97453] - Analysis of TNF-R1: Lane 1: MW marker, Lane 2: Hela (HS), Lane 3: Jurkat.](http://images.novusbio.com/fullsize/TNF-RI-TNFRSF1A-Antibody-Western-Blot-NBP1-97453-img0005.jpg "Western Blot: TNF RI/TNFRSF1A Antibody [NBP1-97453] - TNF-R1 Antibody [NBP1-97453] - Analysis of TNF-R1: Lane 1: MW marker, Lane 2: Hela (HS), Lane 3: Jurkat.")
![Immunohistochemistry-Paraffin: TNF RI/TNFRSF1A Antibody [NBP1-97453] - TNF-R1 Antibody [NBP1-97453] - Analysis of human spleen tissue stained with TNF receptor 1 pAb at 10ug/ml.](http://images.novusbio.com/fullsize/TNF-RI-TNFRSF1A-Antibody-Immunohistochemistry-Paraffin-NBP1-97453-img0004.jpg)
![Flow Cytometry: TNF RI/TNFRSF1A Antibody [NBP1-97453] - TNF Receptor I Antibody [NBP1-97453] - MLL-AF9 transduced murine leukemia cells. Tnfr-/- cells were used as negative control. Image provided by verified customer.](http://images.novusbio.com/fullsize/TNF-RI-TNFRSF1A-Antibody-Flow-Cytometry-NBP1-97453-img0006.jpg)
![Western Blot: Rabbit Polyclonal TNF RI/TNFRSF1A Antibody [NBP1-97453] -Quantification of TNF alpha in bone graft in the tibia of intrailiac cellularized goats at different times compared with tibial autograft and untreated bone defect. NBP1-97453 was used at a dilution of 1:1000 and Beta-actin antibody (Catalog # NB600-501) was used at a dilution of 1:3000. Evaluation of pre-cellularized graft in iliac crest in the treatment of bone defects in the tibia of goats. G1: cellularized graft for 4 weeks applied to tibial bone defect, G2: cellularized graft for 6 weeks applied to tibial bone defect, G3: cellularized graft for 8 weeks applied to tibial bone defect, G4: tibial autograft and G5: untreated bone defect. All groups were evaluated 10 days after graft implantation. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp1-97453_rabbit-polyclonal-tnf-ri-tnfrsf1a-antibody-western-blot-2952025141129.jpg)
![Western Blot: TRAIL/TNFSF10 Antibody (III6F) [NBP1-97640] - Lane 1: Marker [kDa]. Lane 2: 100ng Recombinant Human TRAIL/TNFSF10 Protein (24kDa). Stained with mouse anti-human TRAIL (III6F; 1ug/mL) overnight at 4C, followed by IR dye 680 goat anti-mouse secondary (LI-COR#926-68070; 1:10,000) for 1 hour at room-temperature.](http://images.novusbio.com/fullsize/TRAIL-TNFSF10-Antibody-III6F-Western-Blot-NBP1-97640-img0002.jpg "Western Blot: TRAIL/TNFSF10 Antibody (III6F) [NBP1-97640] - Lane 1: Marker [kDa]. Lane 2: 100ng Recombinant Human TRAIL/TNFSF10 Protein (24kDa). Stained with mouse anti-human TRAIL (III6F; 1ug/mL) overnight at 4C, followed by IR dye 680 goat anti-mouse secondary (LI-COR#926-68070; 1:10,000) for 1 hour at room-temperature.")
![Western Blot: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY TNFRSF10B.](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Western-Blot-NBP2-46148-img0009.jpg "Western Blot: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY TNFRSF10B.")
![Immunohistochemistry: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of Carcinoma of Human thyroid tissue.(Heat-induced epitope retrieval by 1mM EDTA in 10mM Tris buffer (pH8.5) at 120C for 3 min)](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Immunohistochemistry-NBP2-46148-img0008.jpg)
![Immunohistochemistry: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of Adenocarcinoma of Human colon tissue. (Heat-induced epitope retrieval by 1mM EDTA in 10mM Tris buffer (pH8.5) at 120C for 3 min)](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Immunohistochemistry-NBP2-46148-img0001.jpg)
![Immunohistochemistry: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of Human tonsil tissue.(Heat-induced epitope retrieval by 1mM EDTA in 10mM Tris buffer (pH8.5) at 120C for 3 min)](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Immunohistochemistry-NBP2-46148-img0002.jpg)
![Immunohistochemistry: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of Carcinoma of Human kidney tissue.(Heat-induced epitope retrieval by 1mM EDTA in 10mM Tris buffer (pH8.5) at 120C for 3 min)](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Immunohistochemistry-NBP2-46148-img0003.jpg)
![Immunohistochemistry: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of Human lymphoma tissue.(Heat-induced epitope retrieval by 1mM EDTA in 10mM Tris buffer (pH8.5) at 120C for 3 min)](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Immunohistochemistry-NBP2-46148-img0004.jpg)
![Immunohistochemistry: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of Human pancreas tissue. (Heat-induced epitope retrieval by 1mM EDTA in 10mM Tris buffer (pH8.5) at 120C for 3 min)](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Immunohistochemistry-NBP2-46148-img0005.jpg)
![Immunohistochemistry: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of Human lymph node tissue. (Heat-induced epitope retrieval by 1mM EDTA in 10mM Tris buffer (pH8.5) at 120C for 3 min)](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Immunohistochemistry-NBP2-46148-img0006.jpg)
![Immunohistochemistry: TRAIL R2/TNFRSF10B Antibody (2A5) [NBP2-46148] - Analysis of Carcinoma of Human liver tissue.(Heat-induced epitope retrieval by 1mM EDTA in 10mM Tris buffer (pH8.5) at 120C for 3 min)](http://images.novusbio.com/fullsize/TRAIL-R2-TNFRSF10B-Antibody-2A5-Immunohistochemistry-NBP2-46148-img0007.jpg)
![Western Blot: IRF5 Antibody (SD203-07) [NBP2-67742] - Analysis of IRF5 on THP-1 cells lysates using anti-IRF5 antibody at 1/1,000 dilution.](http://images.novusbio.com/fullsize/IRF5-Antibody-SD203-07-Western-Blot-NBP2-67742-img0004.jpg "Western Blot: IRF5 Antibody (SD203-07) [NBP2-67742] - Analysis of IRF5 on THP-1 cells lysates using anti-IRF5 antibody at 1/1,000 dilution.")
![Immunocytochemistry/Immunofluorescence: IRF5 Antibody (SD203-07) [NBP2-67742] - Staining IRF5 in RH-35 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/IRF5-Antibody-SD203-07-Immunocytochemistry-Immunofluorescence-NBP2-67742-img0005.jpg)
![Immunohistochemistry-Paraffin: IRF5 Antibody (SD203-07) [NBP2-67742] - Analysis of paraffin-embedded human spleen tissue using anti-IRF5 antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/IRF5-Antibody-SD203-07-Immunohistochemistry-Paraffin-NBP2-67742-img0003.jpg)
![Flow Cytometry: IRF5 Antibody (SD203-07) [NBP2-67742] - Analysis of Hela cells with IRF5 antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody.](http://images.novusbio.com/fullsize/IRF5-Antibody-SD203-07-Flow-Cytometry-NBP2-67742-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: IRF5 Antibody (SD203-07) [NBP2-67742] - Staining IRF5 in HepG2 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/IRF5-Antibody-SD203-07-Immunocytochemistry-Immunofluorescence-NBP2-67742-img0002.jpg)
![Western Blot: IRF5 Antibody (1G7) [NBP2-45425] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY IRF5.](http://images.novusbio.com/fullsize/IRF5-Antibody-1G7-Western-Blot-NBP2-45425-img0007.jpg "Western Blot: IRF5 Antibody (1G7) [NBP2-45425] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY IRF5.")
![Immunohistochemistry: IRF5 Antibody (1G7) [NBP2-45425] - Analysis of Human lymph node tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-1G7-Immunohistochemistry-NBP2-45425-img0006.jpg)
![Immunohistochemistry: IRF5 Antibody (1G7) [NBP2-45425] - Analysis of Human Kidney tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-1G7-Immunohistochemistry-NBP2-45425-img0001.jpg)
![Immunohistochemistry: IRF5 Antibody (1G7) [NBP2-45425] - Analysis of Human liver tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-1G7-Immunohistochemistry-NBP2-45425-img0002.jpg)
![Immunohistochemistry: IRF5 Antibody (1G7) [NBP2-45425] - Analysis of Adenocarcinoma of Human ovary tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-1G7-Immunohistochemistry-NBP2-45425-img0003.jpg)
![Immunohistochemistry: IRF5 Antibody (1G7) [NBP2-45425] - Analysis of Human pancreas tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-1G7-Immunohistochemistry-NBP2-45425-img0004.jpg)
![Immunohistochemistry: IRF5 Antibody (1G7) [NBP2-45425] - Analysis of Human prostate tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-1G7-Immunohistochemistry-NBP2-45425-img0005.jpg)
![Western Blot: IRF5 Antibody (OTI1G7) - Azide and BSA Free [NBP2-71043] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY IRF5.](http://images.novusbio.com/fullsize/IRF5-Antibody-OTI1G7-Azide-and-BSA-Free-Western-Blot-NBP2-71043-img0001.jpg "Western Blot: IRF5 Antibody (OTI1G7) - Azide and BSA Free [NBP2-71043] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY IRF5.")
![Immunohistochemistry: IRF5 Antibody (OTI1G7) - Azide and BSA Free [NBP2-71043] - Analysis of Human pancreas tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-OTI1G7-Azide-and-BSA-Free-Immunohistochemistry-NBP2-71043-img0006.jpg)
![Immunohistochemistry: IRF5 Antibody (OTI1G7) - Azide and BSA Free [NBP2-71043] - Analysis of Adenocarcinoma of Human ovary tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-OTI1G7-Azide-and-BSA-Free-Immunohistochemistry-NBP2-71043-img0002.jpg)
![Immunohistochemistry: IRF5 Antibody (OTI1G7) - Azide and BSA Free [NBP2-71043] - Analysis of Human Kidney tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-OTI1G7-Azide-and-BSA-Free-Immunohistochemistry-NBP2-71043-img0003.jpg)
![Immunohistochemistry: IRF5 Antibody (OTI1G7) - Azide and BSA Free [NBP2-71043] - Analysis of Human liver tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-OTI1G7-Azide-and-BSA-Free-Immunohistochemistry-NBP2-71043-img0004.jpg)
![Immunohistochemistry: IRF5 Antibody (OTI1G7) - Azide and BSA Free [NBP2-71043] - Analysis of Human lymph node tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-OTI1G7-Azide-and-BSA-Free-Immunohistochemistry-NBP2-71043-img0005.jpg)
![Immunohistochemistry: IRF5 Antibody (OTI1G7) - Azide and BSA Free [NBP2-71043] - Analysis of Human prostate tissue. (Heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)](http://images.novusbio.com/fullsize/IRF5-Antibody-OTI1G7-Azide-and-BSA-Free-Immunohistochemistry-NBP2-71043-img0007.jpg)
![Western Blot: Fas Receptor/TNFRSF6/CD95 Antibody [NBP1-89034] - Fas/TNFRSF6/CD95 Antibody [NBP1-89034] - Analysis in human cell line HDLM-2.](http://images.novusbio.com/fullsize/Fas-TNFRSF6-CD95-Antibody-Western-Blot-NBP1-89034-img0009.jpg "Western Blot: Fas Receptor/TNFRSF6/CD95 Antibody [NBP1-89034] - Fas/TNFRSF6/CD95 Antibody [NBP1-89034] - Analysis in human cell line HDLM-2.")
![Immunocytochemistry/Immunofluorescence: Fas Receptor/TNFRSF6/CD95 Antibody [NBP1-89034] - Fas/TNFRSF6/CD95 Antibody [NBP1-89034] - Immunofluorescent staining of human cell line A-431 shows localization to nuclear bodies, plasma membrane & cytosol. Antibody staining is show in green.](http://images.novusbio.com/fullsize/Fas-TNFRSF6-CD95-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-89034-img0010.jpg)
![<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: Fas/TNFRSF6/CD95 Antibody [NBP1-89034] - Staining in human rectum and skeletal muscle tissues using anti-Fas/TNFRSF6/CD95 antibody. Corresponding Fas/TNFRSF6/CD95 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/Fas-TNFRSF6-CD95-Antibody-Immunohistochemistry-Paraffin-NBP1-89034-img0013.jpg)
![Immunohistochemistry-Paraffin: Fas Receptor/TNFRSF6/CD95 Antibody [NBP1-89034] - Fas/TNFRSF6/CD95 Antibody [NBP1-89034] - Staining of human rectum shows high expression.](http://images.novusbio.com/fullsize/Fas-TNFRSF6-CD95-Antibody-Immunohistochemistry-Paraffin-NBP1-89034-img0011.jpg)
![Immunohistochemistry-Paraffin: Fas Receptor/TNFRSF6/CD95 Antibody [NBP1-89034] - Fas/TNFRSF6/CD95 Antibody [NBP1-89034] - Staining of human skeletal muscle shows low expression as expected.](http://images.novusbio.com/fullsize/Fas-TNFRSF6-CD95-Antibody-Immunohistochemistry-Paraffin-NBP1-89034-img0012.jpg)
![Western Blot: TNF RI/TNFRSF1A Antibody [NBP2-78785] - Total protein from human and mouse liver and placenta was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TNFR1 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using West Pico PLUS chemiluminescence detection reagent.](http://images.novusbio.com/fullsize/TNF-RI-TNFRSF1A-Antibody-Western-Blot-NBP2-78785-img0002.jpg "Western Blot: TNF RI/TNFRSF1A Antibody [NBP2-78785] - Total protein from human and mouse liver and placenta was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TNFR1 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using West Pico PLUS chemiluminescence detection reagent.")
![Immunohistochemistry-Paraffin: TNF RI/TNFRSF1A Antibody [NBP2-78785] - Analysis of a FFPE tissue section of human small intestine using 1:200 dilution of TNFRI antibody (NBP2-78785). The signal was developed using HRP-DAB method which followed counterstaining of the cells with hematoxylin. The antibody generated mainly moderately strong reactivity in glandular cell cytoplasm.](http://images.novusbio.com/fullsize/TNF-RI-TNFRSF1A-Antibody-Immunohistochemistry-Paraffin-NBP2-78785-img0001.jpg)